StockData

Spyre Therapeutics, Inc. (SYRE) stock

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$101.46+7.65 (+8.15%)

Close on Nov 18, 2026Market cap $8.95BP/E –Yield –

Spyre Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

No total debt figures for Spyre Therapeutics

Spyre Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Spyre Therapeutics figures

See a number that looks wrong?